Figures & data
Table 1 Vildagliptin monotherapy studies
Figure 1 Time course of mean HbA1c during one year of treatment with vildagliptin 50 mg once daily (closed triangles) or placebo (open circles).
![Figure 1 Time course of mean HbA1c during one year of treatment with vildagliptin 50 mg once daily (closed triangles) or placebo (open circles).](/cms/asset/c45b5a83-bacd-43fb-beda-b1a619fc5d9f/dvhr_a_31758_f0001_b.jpg)
Figure 2 Change from baseline in HbA1c (A), fasting plasma glucose (B), and weight (C) with vildagliptin 50 mg twice daily in a pooled monotherapy population in patients stratified by age.Citation45 *P < 0.05 versus baseline; baseline values for patients <75 years and ≥75 years were 8.7% and 8.3%, respectively (A); 10.5 mmol/L and 9.7 mmol/L (B); and 86.1 kg and 74.9 kg (C).
![Figure 2 Change from baseline in HbA1c (A), fasting plasma glucose (B), and weight (C) with vildagliptin 50 mg twice daily in a pooled monotherapy population in patients stratified by age.Citation45 *P < 0.05 versus baseline; baseline values for patients <75 years and ≥75 years were 8.7% and 8.3%, respectively (A); 10.5 mmol/L and 9.7 mmol/L (B); and 86.1 kg and 74.9 kg (C).](/cms/asset/2e164154-daea-4e88-b28e-6008c723424c/dvhr_a_31758_f0002_b.jpg)